CHAOUKI STEVEN M 4

What Happened
Steven M. Chaouki, a director of MAIA Biotechnology, Inc. (MAIA), received a grant of 27,907 derivative securities on March 31, 2026. The Form 4 lists the grant as "Acquired" at $0.00 (derivative), reflecting an award of stock options rather than a cash purchase or sale. The filing shows no immediate cash value realized; the award represents the right to buy common stock under the company plan.

Key Details

• Transaction date: 2026-03-31; Form 4 filed: 2026-04-02 (timely filing).
• Transaction type/code: A (Award/Grant) — derivative securities (stock options).
• Quantity: 27,907 options listed as acquired at $0.00 (total reported value $0 on filing).
• Shares owned after transaction: not specified in this Form 4.
• Footnote: The options were granted under MAIA’s 2021 Equity Incentive Plan and "vest 100% on the date of the grant and are exercisable beginning as of that date." (Footnote F1)
• No indication in this filing of a 10b5-1 plan, cashless exercise, tax withholding, or sale of stock tied to this award.

Context
This filing documents an option award (a compensation grant), not a stock purchase or sale. Because the options vest immediately and are exercisable as of the grant date, Chaouki could exercise them right away (though the filing does not show any exercise or sale). Such awards are a common part of executive/director compensation; the Form 4 reports the grant details but does not by itself indicate any buying or selling of underlying shares.